1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Regenicin, Inc.

Regenicin, Inc.

RGIN
Regenicin, Inc.US flagOther OTC
0.00
USD
- -
- -
15,348.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.06
-0.04
-0.05
0.02
- -
-0.01
-0.01
- -
-0.01
- -
- -
- -
-0.01
Free Cash Flow per Basic Share
-0.04
-0.02
-0.01
-0.01
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.06
-0.09
-0.12
-0.08
-0.07
-0.08
-0.08
-0.09
-0.09
-0.09
-0.1
-0.1
-0.11
Tangible Book Value per Share
-0.01
-0.02
-0.04
-0.04
-0.01
- -
-0.01
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.04
Basic Weighted Avg Shares
75
85
89
109
133
153
153
153
153
153
153
153
153
153
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-4
-3
-5
2
- -
-1
-1
-1
-1
-1
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
92.1
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-1
-1
-3
-4
-2
- -
-2
-2
-3
-4
-4
-5
-6
-6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
2
2
- -
-4
-2
- -
-1
-2
-3
-4
-4
-5
-6
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-2.47
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
153
153
153
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
Total Current Assets
- -
12
12
Cash, Cash Equivalents & STI
- -
12
12
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
18
18
Payables & Accruals
5
5
5
ST Debt
1
1
1
Deferred Revenue
- -
12
13

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
106.31%
18.13%
12.89%
Free Cash Flow
61%
-2.47%
13.21%
Net Income, GAAP
-75.43%
-3.6%
-4.67%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-24.79%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Randall E. McCoy
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
10 High Court Little Falls NJ United States of America 07424
IPO Date
Nov 16, 2009
CIK
0001412659
Website
regenicin.com
Similar Companies
Traws Pharma, Inc. (TRAW)
Nanoform Finland Oyj (NANOFH.HE)
Ziccum AB (publ) (ZICC.ST)
Vericel Corporation (VCEL)
Acrivon Therapeutics, Inc. Common Stock (ACRV)
AP Biosciences Inc (6945.TWO)
Business
Regenicin, Inc. is a biotechnology firm dedicated to advancing and commercializing innovative technology for tissue-engineered skin substitutes. The company's primary offering, NovaDerm, is a multi-layered, living skin substitute engineered from a patient's own cells, designed to address severe burns and chronic wounds. This advanced solution aims to facilitate healing and regenerate healthy human skin. Additionally, Regenicin is developing TempaDerm, intended for smaller localized wound care, such as ulcers. These products are central to restoring the qualities of healthy skin, applicable across treatments for burns, persistent wounds, and various reconstructive surgical procedures. The company, initially incorporated in 2007, adopted the name Regenicin, Inc. in July 2010, succeeding its former identity as Windstar, Inc. Regenicin, Inc. is headquartered in Las Vegas, Nevada.